Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes
Restricted accessOtherFirst published online June, 2009
Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes
Introduction. We assessed the influence of genetic polymorphisms in the renin-angiotensin system on the risk of diabetes associated with the use of angiotensin II receptor blockers and angiotensin-converting enzyme (ACE) inhibitors.
Materials and methods. We performed a matched case-control study among antihypertensive drug users. Pharmacy records and questionnaires were used to ascertain incident diabetes (cases), antihypertensive drug use, and risk factors. Controls did not (yet) have diabetes.We genotyped ACE (G4656C, which is in complete linkage disequilibrium with the ACE insertion/deletion polymorphism), angiotensinogen (M235T), and angiotensin II type 1 receptor (A1166C).
Results. Among 495 cases of incident diabetes and 2,624 controls, homozygous 1166C carriers of angiotensin II type 1 receptor who used angiotensin II receptor blockers had an increased risk of diabetes compared to 1166A carriers (interaction odds ratio 5.3 [95% confidence interval: 1.8-16.1]). Homozygous ACE GG subjects who used ACE inhibitors ≥ 1 defined daily dose/day had a higher risk of diabetes compared to subjects with the ACE C allele (interaction odds ratio 2.3 [95% confidence interval: 1.2-4.5]).
Conclusions. Angiotensin II receptor blockers increase the occurrence of diabetes in homozygous 1166C carriers of angiotensin II type 1 receptor, but not in 1166A carriers. ACE inhibitors at doses ≥ 1 defined daily dose/day increase the risk of diabetes among homozygous ACE GG carriers, but not in 4656C carriers.
Messerli FH, Grossman E., Goldbourt U.Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens2001;14:12S-16S.
2.
Grossman E., Messerli FH, Goldbourt U.High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?Arch Intern Med2000; 160:2447-52.
3.
Elliott WJ, Meyer PMIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet2007;369:201-07.
4.
Lam SK, Owen A.Incident diabetes in clinical trials of antihypertensive drugs. Lancet2007;369:1513-4; author reply 1514-5.
5.
Jandeleit-Dahm KA, Tikellis C., Reid CM et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes . J Hypertens2005; 23:463-73.
6.
Spiering W., Kroon AA, Fuss-Lejeune MM et al. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension2000;36:411-16.
7.
Spiering W., Kroon AA, Fuss-Lejeune MJ et al. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens2005 ; 23:753-8.
8.
Hilgers KF, Langenfeld MR, Schlaich M. et al. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation1999;100:1394-9.
9.
Tiret L., Rigat B., Visvikis S. et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet1992;51:197-205.
10.
Rigat B., Hubert C., Alhenc-Gelas F. et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest1990;86:1343-6.
11.
Huang XH, Rantalaiho V., Wirta O. et al. Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet1998;102:372-8.
12.
Bozkurt O., Verschuren WM, van Wieren-de Wijer BM et al. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J Hum Hypertens2008;22:774-80.
13.
van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A. et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci2009;31:158-64.
14.
World Health Organization. Definition, diagnosis and classification of diabetes mellitus. Geneva, 1999. 15. World Health Organization. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology - Nordic Council on Medicines, 1999.
15.
Knaapen AM, Ketelslegers HB, Gottschalk RW et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem2004;50:1664-8.
16.
Veldman BA, Spiering W., Doevendans PA et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens2002;20:2023-7.
17.
Villard E., Tiret L., Visvikis S. et al. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet1996;58:1268-78.
18.
Khoury MJ, Flanders WDNontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls!Am J Epidemiol1996;144:207-13.
19.
Yu HM, Lin SG, Liu GZ et al. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther2006;79:581-9.
20.
Yvan-Charvet L., Even P., Bloch-Faure M. et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes2005;54:991-9.
21.
Jandeleit-Dahm KAM , Tikellis C., Reid CM et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes . J Hypertens2005; 23:463-73.
22.
Gorden P., Sherman BM, Simopoulos APGlucose intolerance with hypokalemia: an increased proportion of circulating proinsulin-like component. J Clin Endocrinol Metab1972;34:235-40.
23.
Rowe JW, Tobin JD, Rosa RM, Andres R.Effect of experimental potassium deficiency on glucose and insulin metabolism . Metabolism1980;29:498-502.
24.
Rapoport MI , Hurd HFThiazide-induced glucose intolerance treated with potassium. Arch Intern Med1964;113:405-08.
25.
Duncan JA, Scholey JW, Miller JAAngiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens2001;1:111-16.
26.
van Geel PP , Pinto YM, Voors AA et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension2000;35:717-21.
27.
Stephens JW , Dhamrait SS, Cooper JA et al. The D allele of the ACE I/D common gene variant is associated with type 2 diabetes mellitus in Caucasian subjects . Mol Genet Metab2005 ;84:83-9.
